Showing 2781-2790 of 4063 results for "".
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/On the eve of World Sight Day, Orbis International is celebrating achievements of the eye health community over the past two decades, and warns of a projected global tripling in demand for eye care over the next 30 years. 2020 is a critical year for Orbis International and other leaders in
- ImprimisRx to Focus on Investments in Quality at the 2019 AAO Meetinghttps://modernod.com/news/imprimisrx-to-focus-on-investments-in-quality-at-the-2019-aao-meeting/2476951/ImprimisRx announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) annual meeting to be held in San Francisco, October 12-15. As part of ImprimisRx’s commitment to quality manufacturing, the company will be discussing its ongoing investments in cGMP (Curre
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- Vision 2020 USA to Hold Annual World Sight Day Briefing on October 17, 2019https://modernod.com/news/vision-2020-usa-to-hold-annual-world-sight-day-briefing-on-october-17-2019/2476939/As part of World Sight Day events, on Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075, in aWashington DC, from noon to 1 p.m. According to Prevent Blindness, by 2050, the impaired and blind populations are projecte
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- American Academy of Optometry Foundation Announces the 2019 Beta Sigma Kappa (BSK) Research Fellowship Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2019-beta-sigma-kappa-bsk-research-fellowship-recipient/2476908/The American Academy of Optometry Foundation (AAOF) in collaboration with the Beta Sigma Kappa International Optometric Honor Society, has announced Sima T. Mozdbar, OD, as the 2019 recipient of the Beta Sigma Kappa (BSK) Research Fellowship. Dr. Mozdbar is an Adjunct Clinical Professor at the Un
- CooperVision Seeks Submissions for 2020 Best Practices Honoreeshttps://modernod.com/news/coopervision-seeks-submissions-for-2020-best-practices-honorees/2476909/Among thousands of eye care professionals at Vision Expo West in Las Vegas, CooperVision announced today its fifth annual search for the nation’s 2020 Best Practices (